Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: A switch to a more resistant phenotype

Human Pathology

Volumn 33, Issue 7, 2002, Pages 686-692

  Van der Woude, C J ^a   Jansen, P L M ^a   Tiebosch, A T G M ^a   Beuving, A ^a   Homan, M ^a   Kleibeuker, J H ^a   Moshage, H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Adenocarcinoma; Apoptosis; Barrett's esophagus; Bax; Bcl 2; Bcl xl; COX 2; Dysplasia; Fas; Gastric metaplasia; iNOS; Intestinal metaplasia

Indexed keywords

CYCLOOXYGENASE 2; FAS ANTIGEN; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTON PUMP INHIBITOR;

ADULT; AGED; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CANCER GRADING; CLINICAL ARTICLE; COLON ADENOMA; COLORECTAL TUMOR; DYSPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MALE; PHENOTYPE; STOMACH ADENOCARCINOMA; STOMACH MUCOSA; TUMOR CELL;

EID: 0036650412     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hupa.2002.124908     Document Type: Article

References (38)

1. The diagnosis of Barrett's esophagus: Goblets, goblets, goblets
2. Natural history of high-grade dysplasia in Barrett's esophagus
3. Barrett's esophagus: Development of dysplasia and adenocarcinoma
4. High-resolution endoluminal sonography is a sensitive modality for the identification of Barrett's metaplasia
5. Surveillance of patients with Barrett's esophagus for dysplasia and cancer with balloon cytology
6. Mucin histochemistry of the columnar epithelium of the oesophagus (Barrett's oesophagus): A prospective biopsy study
7. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma
8. Long term omeprazole treatment of patients with Barrett's oesophagus
9. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: Immediate and mid term results
10. The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia
11. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus
12. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX
13. Nitric oxide and apoptosis
14. Up-regulation of cyclooxygenase 2 gene expression in human colo-rectal adenomas and adenocarcinomas
15. Expression of cyclooxygenase- 2 in human gastric carcinoma
16. Sulindac and polyp regression
17. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis
18. The histologic spectrum of Barrett's esophagus
19. Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical application
20. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas
21. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: A comparative study
22. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus
23. Barrett's esophagus, apoptosis and cell cycle regulation: Correlation of p53 with Bax, Bcl- 2, and p21 protein expression
24. Bcl-2 family members and the mitochondria in apoptosis
25. p53 protein accumulation is a specific marker of malignant potential in Barrett's metaplasia
26. Tumor suppressor p 53 is a direct transcriptional activator of the human bax gene
27. Cell death induced by the Fas/Fas ligand pathway and its role in pathology
28. Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus
29. Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma
30. Overexpression of Fas ligand during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus
31. Fas and Fas ligand in gut and liver
32. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma. Ex vivo induction by bile salts and acid exposure
33. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence
34. Post-ablation biomarker abnormalities in Barrett's esophagus (BE): Are we increasing the cancer risk?
35. NSAIDs do not protect patients with Barrett oesophagus from adenocarcinoma development
36. Endoscopic regression of Barrett's oesophagus during omeprazole treatment: A randomized double blind study
37. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression